Akeso completed a follow-on equity offering of 20,000,000 ordinary shares at HK$97.76 per share, raising about HK$1.96b, after recently reporting first patient dosing in a Phase III trial of cadonilimab in perioperative MSI H or dMMR colon cancer.
The capital raise strengthens Akeso's funding…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.